CUMULATIVE
SUPPLEMENT 1

JAN'94



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

14TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION

APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS

14TH EDITION

Cumulative Supplement 1

JANUARY 1994

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

14TH EDITION

CUMULATIVE SUPPLEMENT 1

JANUARY 1994

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 14th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Additions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is then dropped in subsequent Cumulative Supplements for that item.

Deletions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >DLT> (DELETE) to the left of the line containing overstruck print. The >DLT> symbol is dropped in subsequent Cumulative Supplements for that item. The overstruck print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements for this edition. However, the overstruck print in the Patent and Exclusivity Data is dropped in subsequent Cumulative Supplements.

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the " ə " symbol to designate their non-marketed status. All products having a " ə " symbol in the 12th Cumulative Supplement of the 14th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 15th Edition.

1.2 PRODUCTS REQUIRING REVISED LABELING FOR FULL APPROVAL

Drug products in this category (1) initially received approval only on the basis of safety before effectiveness studies were required, or (2) were conditionally approved under the temporary exemption that allowed these products to be marketed while effectiveness studies were being conducted. Listed below are those drugs which are now required to revise their labeling and provide additional information necessary for full approval on the basis of requirements listed in the Federal Register. As approval is granted by the Agency for a specific product, based on additional information submitted by the applicant, the product will be included in the appropriate Drug Product List.

Products	Federal Register Reference
Nitroglycerin (capsule, controlled release;oral)	SEP 07, 1984 (49 FR 35428)
Nitroglycerin (film, extended release; transdermal*)	JUL 15, 1993 (58 FR 38129)
Nitroglycerin (tablet, controlled release;oral)	SEP 07, 1984 (49 FR 35428)
Nitroglycerin (tablet, controlled release;buccal)	JUL 05, 1985 (50 FR 27688)

*The Federal Register of July 15, 1993 (58 FR 38129) announced that the FDA was revoking the temporary exemption for nitroglycerin in a transdermal delivery system. Marketing of a drug product that is the subject of a conditionally approved ANDA may continue by meeting the requirements listed in the Federal Register. Firms wishing to submit a new ANDA before a drug product is approved (NDA or ANDA) and appears in the List should submit a 505(b)(2) application following the directions contained in the Federal Register. Nitro-Dur has been selected as the reference listed drug. The preamble to the final rule (57 FR 17958) states if there are multiple NDA's, the reference listed drug generally will be the market leader. This is the basis upon which Nitro-Dur was selected. In addition, the preamble states that, in multiple NDA situations, a product not designated as the reference listed drug and not shown to be bioequivalent to the reference listed drug may be shielded from generic competition. This is the case with Summit's Transderm-Nitro. The Office of Generic Drugs (OGD) has been requested to have a second listed drug as provided for in the Final Rule. OGD has granted this request. Therefore, at the time that Schering's and Summit's supplements are fully approved and their products are entered into the List, we will have two reference listed drugs for the nitroglycerin transdermal systems. Firms may, therefore, elect to conduct bioequivalence studies against either of these products. It is conceivable that a non-referenced listed drug may be fully approved and appear in the List; in this case, the Agency's referenced listed drug will not change and a 505(b)(2) application will be appropriate until the reference listed drugs are fully approved. Once they are fully approved, a 505(j) application will be the appropriate mechanism for an ANDA submission.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant; or when an applicant changes its name; or when an applicant name is changed to meet internal publication standards. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial approved product lines are transferred between applicants, each approved product involved will appear as an applicant name change in the Cumulative Supplement.

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)

THERE WERE NO APPLICANT NAME CHANGES IN JANUARY 1994.

1.4 USP MONOGRAPH TITLE ADDITIONS OR CHANGES

The U.S. Pharmacopeia (USP) periodically makes additions to or changes in monograph titles. Some of these additions or changes may affect dosage form terms listed in *Approved Drug Products with Therapeutic Equivalence Evaluations* (ADP). Instead of making the change in each affected product, the Cumulative Supplement (CS) will list applicable monograph title and dosage form additions or changes in this section. These will appear as soon as the modified USP monograph title is official. It is possible for these additions or changes to be listed in this section before all applicant holders have made labeling modifications.

The monograph title additions or changes shown below will remain in this section in each succeeding supplement of this edition. Once the next edition of the ADP is published, the products affected by the title additions or changes will be displayed with the new dosage form in the appropriate drug list. As notification to the reader, these monograph title additions or changes will also be listed in a special section of the ADP.

USP MONOGRAPH TITLE ADDITIONS OR CHANGES

FORMER USP MONOGRAPH TITLE (FORMER ADP DOSAGE FORM; ROUTE)	NEW USP MONOGRAPH TITLE (NEW ADP DOSAGE FORM; ROUTE)

THERE WERE NO USP MONOGRAPH TITLE ADDITIONS OR CHANGES DURING THE MONTH OF JANUARY 1994.

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1993) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1993	MAR 1994	JUN 1994	SEP 1994
DRUG PRODUCTS LISTED	9140			
SINGLE SOURCE	2144 (23.5%)			
MULTISOURCE	6996 (76.5%)			
THERAPEUTICALLY EQUIVALENT	6292 (68.8%)			
NOT THERAPEUTICALLY EQUIVALENT	527 (5.8%)			
EXCEPTIONS[1]	177 (1.9%)			
NEW MOLECULAR ENTITIES APPROVED	--			
NUMBER OF APPLICANTS	526			

[1]Amino acid-containing products of varying composition (see Introduction, page xvii of the List).

ALPRAZOLAM

TABLET; ORAL
ALPRAZOLAM

>ADD >	AB	MYLAN	0.25MG	N74215 001 JAN 27, 1994
>ADD >				
>ADD >	AB		0.5MG	N74215 002 JAN 27, 1994
>ADD >				
>ADD >	AB		1MG	N74215 003 JAN 27, 1994
>ADD >				
>ADD >	AB		2MG	N74215 004 JAN 27, 1994
>ADD >				

BACLOFEN

TABLET; ORAL
BACLOFEN

>ADD >	AB	ROYCE	10MG	N73092 001 JAN 28, 1994
>ADD >				
>ADD >	AB		20MG	N73093 001 JAN 28, 1994
>ADD >				

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

>DLT >		/CEFADROXIL/		
>DLT >	/AB/	/ZENITH/	/EQ 500MG BASE/	/N62766/001/ /MAR/03,/1987/
>DLT >				
>ADD >		∂ ZENITH	EQ 500MG BASE	N62766 001 MAR 03, 1987
>ADD >				

TABLET; ORAL

>DLT >		/CEFADROXIL/		
>DLT >	/AB/	/ZENITH/	/EQ 1GM BASE/	/N62774/001/ /APR/08,/1987/
>DLT >				
>ADD >		∂ ZENITH	EQ 1GM BASE	N62774 001 APR 08, 1987
>ADD >				

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL
PERIDEX

>ADD >	AT	+ P AND G	0.12%	N19028 001 AUG 13, 1986
>ADD >				
>ADD >		PERIOGARD		
>ADD >	AT	COLGATE PALMOLIVE	0.12%	N73695 001 JAN 14, 1994
>ADD >				

CHLORTHALIDONE

TABLET; ORAL
THALITONE

>ADD >		+ HORUS	15MG	N19574 001 DEC 20, 1988
>ADD >				
>DLT >			/15MG/	/N19574/001/ /DEC/20,/1988/
>DLT >				

ERYTHROMYCIN

SOLUTION; TOPICAL
ERYTHROMYCIN

>ADD >	AT	BAUSCH AND LOMB	2%	N64039 001 JAN 27, 1994
>ADD >				

METHAZOLAMIDE

TABLET; ORAL
METHAZOLAMIDE

>ADD >	AB	MIKART	25MG	N40062 001 JAN 27, 1994
>ADD >				
>ADD >	AB		50MG	N40062 002 JAN 27, 1994
>ADD >				

METOPROLOL TARTRATE

TABLET; ORAL
METOPROLOL TARTRATE

>ADD >	AB	APOTHECON	50MG	N74258 001 JAN 27, 1994
>ADD >				
>ADD >	AB		100MG	N74258 002 JAN 27, 1994
>ADD >				
>ADD >	AB	COPLEY	50MG	N74333 001 JAN 27, 1994
>ADD >				
>ADD >	AB		100MG	N74333 002 JAN 27, 1994
>ADD >				

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM

>ADD >	AB	COPLEY	EQ 250MG BASE	N74289 001 JAN 27, 1994
>ADD >				
>ADD >	AB		EQ 500MG BASE	N74289 002 JAN 27, 1994
>ADD >				

PINDOLOL

TABLET; ORAL
PINDOLOL

> ADD >	AB		MUTUAL PHARM	5MG	N74063 001
> ADD >					JAN 27, 1994
> ADD >	AB			10MG	N74063 002
> ADD >					JAN 27, 1994

PIROXICAM

CAPSULE; ORAL
PIROXICAM

> ADD >	AB		NOVOPHARM	10MG	N73637 001
> ADD >					JAN 28, 1994
> ADD >	AB			20MG	N73638 001
> ADD >					JAN 28, 1994

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
ISOPTIN SR

> ADD >	AB	+	KNOLL	180MG	N19152 002
> ADD >					DEC 15, 1989

VERAPAMIL HCL

> ADD >	AB		BAKER NORTON	180MG	N74330 001
> ADD >					JAN 31, 1994

>_ADD_> NAPROXEN SODIUM

>_ADD_> TABLET; ORAL
>_ADD_> ALEVE
>_ADD_> HAMILTON PHARMS EQ 200MG BASE N20204 002
>_ADD_> JAN 11, 1994

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST
CUMULATIVE SUPPLEMENT NUMBER 1 / JAN '94

NO JANUARY 1994 APPROVALS

LIST OF ORPHAN PRODUCT DESIGNATIONS & APPROVALS

[January, 1994]

NAME *Generic/Chemical* *TN= Trade Name*	***INDICATION DESIGNATED***	***SPONSOR & ADDRESS*** *DD= Date Designated* *MA= Marketing Approval*
AMMONIUM TETRATHIOMOLYBDATE TN=	TREATMENT OF WILSON'S DISEASE.	BREWER, GEORGE J. M.D. UNIVERSITY OF MICHIGAN MEDICAL SCHOOL ANN ARBOR MI 48109-0618 DD 01/31/94 MA / /
ANTIVENIN, POLYVALENT CROTALID (OVINE) FAB TN= CROTAB	TREATMENT OF ENVENOMATIONS INFLICTED BY NORTH AMERICAN CROTALID SNAKES.	THERAPEUTIC ANTIBODIES INC. 1500 21ST AVENUE SOUTH, SUITE 310 NASHVILLE TN 37212 DD 01/12/94 MA / /
RECOMBINANT HUMAN GELSOLIN TN=	TREATMENT OF THE RESPIRATORY SYMPTOMS OF CYSTIC FIBROSIS.	BIOGEN, INC. 14 CAMBRIDGE CENTER CAMBRIDGE MA 02124 DD 01/12/94 MA / /
TIZANIDINE HCL TN= ZANAFLEX	TREATMENT OF SPASTICITY ASSOCIATED WITH MULTIPLE SCLEROSIS AND SPINAL CORD INJURY.	ATHENA NEUROSCIENCES, INC. 800F GATEWAY BOULEVARD SOUTH SAN FRANCISCO CA 94080 DD 01/31/94 MA / /

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY
IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO JANUARY 1994 ADDITIONS

BIOPHARMACEUTIC GUIDANCE AVAILABILITY

DRUG NAME (DOSAGE FORM) DATE REVISED DATE

THE FOLLOWING IS A LIST OF GUIDANCES AVAILABLE FOR *IN VIVO* BIOEQUIVALENCE STUDIES AND *IN VITRO* DISSOLUTION TESTING. COMMENTS AND SUGGESTIONS CONCERNING THESE GUIDANCES ARE ENCOURAGED AND SHOULD BE SENT TO THE DIVISION OF BIOEQUIVALENCE (HFD-650, MPN-2 ROOM 279) 5600 FISHERS LANE, ROCKVILLE, MD 20857.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 13TH EDITION FOR A FULL LISTING OF BIOPHARMACEUTIC GUIDANCE AVAILABILITY DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

ALBUTEROL (METERED DOSE INHALER - *IN VIVO)* JAN 27, 1994

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS

THE FOLLOWING ARE TWO LISTS OF PETITIONS FILED UNDER SECTION 505(j)(2)(C) OF THE ACT WHERE THE AGENCY HAS DETERMINED THAT THE REFERENCED PRODUCT: (1) IS SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS APPROVED) OR (2) IS NOT SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS DENIED). THE DETERMINATION THAT AN ANDA WILL BE APPROVED IS NOT MADE UNTIL THE ANDA ITSELF IS SUBMITTED AND REVIEWED BY THE AGENCY. A COPY OF EACH PETITION IS LISTED BY DOCKET NUMBER ON PUBLIC DISPLAY IN FDA'S DOCKETS MANAGEMENT BRANCH, HFA-305, ROOM 4-62, 5600 FISHERS LANE, ROCKVILLE, MD 20857.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 13TH EDITION FOR A FULL LISTING OF ANDA SUITABILITY PETITIONS DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

NO ANDA SUITABILITY PETITIONS APPROVED OR DENIED IN JANUARY 1994.

EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE EXCLUSIVITY COLUMN, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 14TH EDITION FOR A FULL LISTING OF EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

REFERENCES

NEW INDICATION

I-99 PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER

I-100 TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY

I-101 TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	18343 001	CAPTOPRIL; CAPOTEN				I-101	JAN 28, 1997
>ADD>	18343 002	CAPTOPRIL; CAPOTEN				I-101	JAN 28, 1997
>ADD>	18343 003	CAPTOPRIL; CAPOTEN				I-101	JAN 28, 1997
>ADD>	18343 005	CAPTOPRIL; CAPOTEN				I-101	JAN 28, 1997
>ADD>	19304 001	FENOFIBRATE; LIPIDIL	4058552	NOV 15, 1994		NCE	DEC 31, 1998
>ADD>	19949 001	FLUCONAZOLE; DIFLUCAN	4416682	NOV 22, 2000		I-100	DEC 30, 1996
>ADD>	19949 002	FLUCONAZOLE; DIFLUCAN	4416682	NOV 22, 2000		I-100	DEC 30, 1996
>ADD>	19949 003	FLUCONAZOLE; DIFLUCAN	4416682	NOV 22, 2000		I-100	DEC 30, 1996
>ADD>	19950 001	FLUCONAZOLE; DIFLUCAN	4416682	NOV 22, 2000		I-100	DEC 30, 1996
>ADD>	20219 001	LEVOCABASTINE HYDROCHLORIDE; LIVOSTIN	4369184	JAN 18, 2000		NCE	NOV 10, 1998
>ADD>	20264 001	MEGESTROL ACETATE; MEGACE				NDF	SEP 10, 1997
>ADD>	20279 001	PREDNICARBATE; DERMATOP				NDF	OCT 29, 1996
>ADD>	19627 001	PROPOFOL; DIPRIVAN				I-99	OCT 26, 1996
>ADD>	20284 001	SULFAMETHOXAZOLE; SEPTRA	4209513	JUN 24, 1997			
>ADD>	20284 002	SULFAMETHOXAZOLE; SEPTRA DS	4209513	JUN 24, 1997			
>ADD>	20326 001	TRIMETREXATE GLUCURONATE; NEUTREXIN				ODE	DEC 17, 2000

*U.S. Government Printing Office: 1994 — 301-037/80008